PAUL D RUBIN, the Chief Medical Officer of $BIOA, sold 7,433 shares of the company on 02-02-2026 for an estimated $139,368. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares of this class of stock. Following this trade, they now own 0 shares of this class of $BIOA stock.
$BIOA Insider Trading Activity
$BIOA insiders have traded $BIOA stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $BIOA stock by insiders over the last 6 months:
- KRISTEN FORTNEY (Chief Executive Officer) sold 233,107 shares for an estimated $4,223,036
- PAUL D RUBIN (Chief Medical Officer) has made 0 purchases and 4 sales selling 101,763 shares for an estimated $1,152,767.
- DOV A MD GOLDSTEIN (Chief Financial Officer) has made 0 purchases and 4 sales selling 27,000 shares for an estimated $531,827.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BIOA Hedge Fund Activity
We have seen 45 institutional investors add shares of $BIOA stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 270,479 shares (+749.8%) to their portfolio in Q3 2025, for an estimated $1,590,416
- VANGUARD GROUP INC removed 236,477 shares (-14.3%) from their portfolio in Q4 2025, for an estimated $3,128,590
- CANTOR FITZGERALD, L. P. removed 200,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,176,000
- ORBIMED ADVISORS LLC removed 131,058 shares (-14.2%) from their portfolio in Q3 2025, for an estimated $770,621
- GEODE CAPITAL MANAGEMENT, LLC added 109,276 shares (+24.1%) to their portfolio in Q3 2025, for an estimated $642,542
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 71,071 shares (+59.1%) to their portfolio in Q3 2025, for an estimated $417,897
- GOLDMAN SACHS GROUP INC added 64,886 shares (+261.7%) to their portfolio in Q3 2025, for an estimated $381,529
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BIOA Analyst Ratings
Wall Street analysts have issued reports on $BIOA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 10/29/2025
To track analyst ratings and price targets for $BIOA, check out Quiver Quantitative's $BIOA forecast page.
$BIOA Price Targets
Multiple analysts have issued price targets for $BIOA recently. We have seen 3 analysts offer price targets for $BIOA in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Yasmeen Rahimi from Piper Sandler set a target price of $73.0 on 01/27/2026
- Jeffrey Hung from Morgan Stanley set a target price of $12.0 on 12/08/2025
- Samantha Semenkow from Citigroup set a target price of $15.0 on 10/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
